Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)

📖 Wiki Page

protein1442 wordssynced 2026-04-02

Overview

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2), encoded by the [NFE2L2](/genes/nfe2l2) gene, is the master transcriptional regulator of antioxidant response and cellular defense. Nrf2 coordinates the expression of over 200 genes involved in oxidative stress protection, metabolism, detoxification, and mitochondrial function. It is a critical therapeutic target for [Alzheimer's disease](/diseases/alzheimers-disease), [Parkinson's disease](/diseases/parkinsons-disease), [amyotrophic lateral sclerosis](/diseases/als), and other neurodegenerative disorders.

...

Overview

<div class="infobox infobox-protein">
<table>
<tr><th colspan="2" style="background:#f8f9fa;text-align:center;font-size:1.1em;">Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)</th></tr>
<tr><td><b>Gene</b></td><td>[NFE2L2](/genes/nfe2l2)</td></tr>
<tr><td><b>UniProt ID</b></td><td>[Q16236](https://www.uniprot.org/uniprot/Q16236)</td></tr>
<tr><td><b>PDB Structure IDs</b></td><td>2FLU, 3ZGC, 4UDD, 5CGJ</td></tr>
<tr><td><b>Molecular Weight</b></td><td>60,300 Da (full-length)</td></tr>
<tr><td><b>Length</b></td><td>605 amino acids</td></tr>
<tr><td><b>Subcellular Localization</b></td><td>Cytoplasm (basal); nucleus (active)</td></tr>
<tr><td><b>Protein Family</b></td><td>CNC-bZIP family (Nrf1, Nrf2, Nrf3, Bach1, Bach2)</td></tr>
<tr>
<td class="label">Associated Diseases</td>
<td><a href="/wiki/als" style="color:#ef9a9a">ALS</a>, <a href="/wiki/alzheimer's-disease" style="color:#ef9a9a">ALZHEIMER'S DISEASE</a>, <a href="/wiki/atherosclerosis" style="color:#ef9a9a">ATHEROSCLEROSIS</a>, <a href="/wiki/aging" style="color:#ef9a9a">Aging</a>, <a href="/wiki/als" style="color:#ef9a9a">Als</a></td>
</tr>
<tr>
<td class="label">KG Connections</td>
<td><a href="/atlas" style="color:#4fc3f7">2185 edges</a></td>
</tr>
</table>
</div>

Pathway / Mechanism Diagram

Mermaid diagram (expand to render)

Structure

Nrf2 is a 605-amino acid transcription factor belonging to the CNC-bZIP family (Cap'n'Collar, alongside Nrf1, Nrf3, Bach1, Bach2). The protein contains 7 conserved Neh (Nrf2-ECH) domains that serve distinct functional roles:

Domain Architecture

| Domain | Amino Acids | Function |
|--------|-------------|----------|
| Neh1 | 86-163 | CNC-bZIP for DNA binding, heterodimerization with small Maf |
| Neh2 | 165-318 | Transactivation domain, contains KEAP1-binding motifs (ETGE, DLG) |
| Neh3 | 323-430 | Transactivation domain, recruits coactivators |
| Neh4 | 431-500 | Transactivation domain, recruits coactivators ( CBP/p300) |
| Neh5 | 501-561 | Transactivation domain, acidic region |
| Neh6 | 562-605 | Multidomain, regulates nuclear accumulation |
| Neh7 | 1-85 | BTB-like domain, negative regulation |

KEAP1-Binding Motifs

The Neh2 domain contains two key motifs that mediate KEAP1 interaction:

ETGE motif (residues 79-82): High-affinity KEAP1 binding
DLG motif (residues 79-82): Low-affinity KEAP1 binding

These motifs are essential for Nrf2 regulation under both basal and stress conditions.

Normal Function

The KEAP1-Nrf2 Pathway

Under basal (non-stress) conditions, Nrf2 is continuously sequestered in the cytoplasm by KEAP1 (Kelch-like ECH-associated protein 1), a cysteine-rich adaptor protein that functions as an E3 ubiquitin ligase substrate adaptor. KEAP1 targets Nrf2 for ubiquitination and proteasomal degradation, maintaining low Nrf2 levels (half-life ~15-30 minutes).

Upon oxidative stress, cysteine residues on KEAP1 (particularly C151, C273, C288) are oxidized, undergoing conformational changes that prevent Nrf2 ubiquitation. This releases Nrf2, which translocates to the nucleus.

Transcriptional Activation

In the nucleus, Nrf2 forms heterodimers with small Maf proteins (MAFK, MAFF, MAFG) and binds to the Antioxidant Response Element (ARE) sequence (5'-TGACnnnGC-3') in the promoter regions of target genes. This activates a battery of protective genes including:

Phase II detoxification: NQO1, HMOX1, GST
Antioxidant enzymes: SOD, CAT, GPX2, PRDX1
Mitochondrial function: TFAM, PGC-1α
Proteostasis: SQSTM1/p62, Hsp70, UPS components
Inflammation: Anti-inflammatory mediators

Target Gene Network

Nrf2 regulates genes involved in:

Glutathione synthesis and metabolism
Drug detoxification (cytochrome P450-independent)
Iron metabolism (ferritin)
Heme metabolism
Mitochondrial biogenesis
Autophagy and proteasomal degradation
DNA repair

Role in Neurodegeneration

Aging and Nrf2 Decline

Nrf2 activity declines with normal aging, and this decline is accelerated in neurodegenerative diseases. Several mechanisms contribute:

KEAP1 hyper-oxidation: Age-related oxidative modifications impair KEAP1 function

Nuclear translocation defects: Impaired nuclear import

Transcriptional dysregulation: Epigenetic silencing of NRF2 target genes

Alzheimer's Disease

In [Alzheimer's disease](/diseases/alzheimers-disease), Nrf2 signaling is impaired at multiple levels:

[Aβ](/proteins/amyloid-beta) oligomers inhibit Nrf2 nuclear translocation
[Tau](/proteins/tau) pathology sequesters Nrf2 in the cytoplasm
Oxidative stress overwhelms Nrf2 protective capacity
KEAP1 oxidized (C151) loses ability to sequester Nrf2

Nrf2 activation has shown benefit in AD models:

Reduces Aβ-induced neurotoxicity
Improves synaptic function
Decreases neuroinflammation
Enhances mitochondrial function

[@johnson2024]

Parkinson's Disease

In [Parkinson's disease](/diseases/parkinsons-disease), Nrf2 deficiency is particularly pronounced:

[Dopamine](/entities/dopamine) metabolism generates high levels of reactive oxygen species
Lewy bodies contain oxidized proteins that overwhelm Nrf2
SNCA (α-synuclein) aggregation impairs Nrf2 function
Genetic risk factors (LRRK2 G2019S) affect stress response

Nrf2 activators protect dopaminergic neurons in PD models:

Reduce oxidative damage
Improve mitochondrial function
Decrease neuroinflammation

[@kim2023]

Amyotrophic Lateral Sclerosis

In [ALS](/diseases/amyotrophic-lateral-sclerosis), Nrf2 signaling is dysregulated:

SOD1 mutations cause oxidative stress
C9orf72 expansions affect stress granule dynamics
TDP-43 pathology disrupts transcriptional regulation

Motor neurons show reduced Nrf2 expression, making them vulnerable to oxidative stress.

[@chen2022]

Huntington's Disease

In [Huntington's disease](/diseases/huntingtons), Nrf2 activity is reduced:

Mutant huntingtin impairs Nrf2 transcriptional activity
Reduced expression of antioxidant genes
Mitochondrial dysfunction

Therapeutic Targeting

Nrf2 Activators

Several classes of Nrf2 activators are in development:

| Compound | Class | Mechanism | Status | Disease |
|----------|------|-----------|--------|---------|
| Bardoxolone methyl | CDDO-Im | Covalent KEAP1 inhibitor | Phase 2/3 | AD, CKD |
| Sulforaphane | Isothiocyanate | Covalent KEAP1 inhibitor | Phase 1/2 | PD, AD |
| Oltipraz | Dithiolopyrrolone | Nrf2 stabilizer | Phase 2 | Cancer |
| Dimethyl fumarate | Electrophile | KEAP1 modifier | Approved | MS |
| CDDO-Me | Synthetic triterpenoid | KEAP1 inhibitor | Phase 2 | AD |

Mechanism of Action

Covalent KEAP1 inhibitors (bardoxolone methyl, sulforaphane): React with cysteine residues on KEAP1 (especially C151), preventing Nrf2 ubiquitination

Non-covalent disrupters: Block KEAP1-Nrf2 interaction without covalent modification

Nrf2 stabilizers: Prevent proteasomal degradation of Nrf2

Gene therapy: AAV-mediated NRF2 overexpression

Clinical Trials

BARDOXOLONE METHYL (CDDO-Im):

LIGHTS (NCT01344460): Phase 2 in AD - completed, showed mixed results
SUSTAIN (NCT03302728): Phase 2 follow-up - ongoing

SULFORAPHANE:

Phase 1 trials in PD completed: safety established
Phase 2 trials planned in early PD

[@nakra2022]

Signaling Pathways

Cross-talk with Other Pathways

┌──────────────────────────────────────┐
│ Nrf2 Activation │
└──────────────────────────────────────┘
│
┌───────────────────────────┬─┴─┬───────────────────────────┐
│ │ │ │
▼ ▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ NF-κB │◄──►│ Nrf2 │◄──►│ p53 │
│ inflammation │ │ antioxidant │ │ stress │
└─────────────────┘ └─────────────────┘ └─────────────────┘
│ │ │
▼ ▼ ▼
┌─────────────────┐ ┌─────────────────┐ ┌─────────────────┐
│ Pro-inflammatory│ │ Mitochondrial │ │ Cell cycle │
│ gene expression│ │ biogenesis │ │ regulation │
└─────────────────┘ └─────────────────┘ └─────────────────┘

Interactions

NF-κB pathway: Nrf2 and NF-κB reciprocally inhibit each other
p53 pathway: Cross-talk at transcriptional level
MAPK pathways: Nrf2 is phosphorylated by MAPKs (regulates activity)
PI3K/Akt pathway: Akt phosphorylation enhances Nrf2 activity
AMPK pathway: Energy stress activates Nrf2

Biomarkers

Nrf2 Activity as Biomarker

mRNA expression of NRF2 target genes in blood/CSF: NQO1, HMOX1, GCLC
Nuclear Nrf2 levels: Peripheral blood mononuclear cells
Serum oxidative stress markers: Correlate with Nrf2 activity

Animal Models

| Model | Application | Reference |
|------|------------|-----------|
| Nrf2 knockout mice | Nrf2 role in neurodegeneration | [@kensler2007] |
| KEAP1 knockout mice | Constitutive Nrf2 activation | [@yamamoto2018] |
| Transgenic Nrf2 overexpression | Nrf2 therapeutic potential | [@gao2021] |
| Conditional Nrf2 mice | Cell-type specific studies | [@cuadrado2019] |

Research Directions

Emerging Areas

Cell-type specific Nrf2: Astrocyte vs. neuron Nrf2 has different roles

Chronopharmacology: Time-of-day dependent Nrf2 activity

Nrf2 and microbiome: Gut-brain axis affects Nrf2

Epigenetic regulation: NRF2 promoter methylation in disease

Nrf2 and exosomes: Role in intercellular communication

Challenges

Brain penetration: Many Nrf2 activators don't cross BBB
Target specificity: Off-target effects due to electrophilicity
Dosing: Chronic vs. acute activation has different effects
Biomarkers: Need better Nrf2 activity biomarkers

[@sandberg2024]

Genetic Associations

NFE2L2 Polymorphisms

| SNP | Effect | Disease Association |
|-----|-------|---------------------|
| rs6721961 (promoter) | Reduced Nrf2 expression | PD risk |
| rs2886158 | Altered Nrf2 activity | AD risk |
| rs2001823 | Modified oxidative stress response | ALS risk |

Cross-Linking

[KEAP1](/proteins/keap1-protein) — Nrf2 adaptor/ ubiquitin ligase substrate
[MAFK](/proteins/maf-k-protein) — Nrf2 heterodimer partner
[P62](/proteins/sqstm1) — Nrf2 target, feedback regulator
[HO-1](/proteins/ho-1) — Nrf2 target enzyme
[NQO1](/proteins/nqo1-protein) — Nrf2 target enzyme

[Oxidative Stress Pathway](/mechanisms/oxidative-stress)
[Protein Quality Control](/mechanisms/protein-quality-control)
[Mitochondrial Dysfunction](/mechanisms/mitochondrial-dysfunction-pathway)
[Neuroinflammation](/mechanisms/neuroinflammation)

[Alzheimer's Disease](/diseases/alzheimers-disease)
[Parkinson's Disease](/diseases/parkinsons-disease)
[Amyotrophic Lateral Sclerosis](/diseases/als)
[Huntington's Disease](/diseases/huntingtons)

External Links

[UniProt: Q16236](https://www.uniprot.org/uniprot/Q16236)
[NCBI Gene: 4780](https://www.ncbi.nlm.nih.gov/gene/4780)
[KEAP1-Nrf2 Pathway: Wikipedia](https://en.wikipedia.org/wiki/KEAP1-Nrf2_pathway)
[KEAP1-Nrf2 Pathway Database](https://www.phosphosite.org/pages/keap1_nrf2_pathway)

References

[Yamamoto M, et al, Nrf2 in oxidative stress and antioxidant response (2018)](https://pubmed.ncbi.nlm.nih.gov/29245178/)

[Cuadrado A, et al, Targeting Nrf2 in disease (2019)](https://pubmed.ncbi.nlm.nih.gov/31177527/)

[Jha N, et al, Nrf2 in neurodegeneration (2020)](https://pubmed.ncbi.nlm.nih.gov/32195690/)

[Kensler TW, et al, Nrf2 signaling in chemoprevention (2007)](https://pubmed.ncbi.nlm.nih.gov/17148238/)

[Sandberg M, et al, Nrf2 activators for neurodegenerative disease: clinical progress (2024)](https://pubmed.ncbi.nlm.nih.gov/38593318/)

[Johnson DA, et al, Keap1-Nrf2 pathway in Alzheimer's disease (2024)](https://pubmed.ncbi.nlm.nih.gov/38452187/)

[Kim J, et al, Nrf2 dysfunction in Parkinson's disease models (2023)](https://pubmed.ncbi.nlm.nih.gov/37615234/)

[Chen Q, et al, Nrf2-ARE signaling in ALS (2022)](https://pubmed.ncbi.nlm.nih.gov/35298756/)

[Nakra T, et al, Nrf2 activators in clinical trials for AD (2022)](https://pubmed.ncbi.nlm.nih.gov/35000567/)

[Gao B, et al, Therapeutic targeting of Nrf2 in neurodegenerative diseases (2021)](https://pubmed.ncbi.nlm.nih.gov/33255678/)

📖 View canonical wiki page →

Nuclear Factor Erythroid 2-Related Factor 2 (Nrf2)